| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EDN1 |
| Uniprot No | P05305 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-73aa |
| 氨基酸序列 | CSCSSLMDKECVYFCHLDIIW |
| 预测分子量 | 29.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EDN1(内皮素1)重组蛋白的3-4篇参考文献的简要信息：
---
1. **文献名称**：**"Cloning and expression of human endothelin-1 receptor cDNA"**
**作者**：Yanagisawa M, et al.
**摘要**：该研究首次成功克隆并表达了人EDN1受体(ETA和ETB亚型)的cDNA，揭示了EDN1与受体结合的分子机制，为后续研究EDN1信号通路及重组蛋白的功能提供了基础。
---
2. **文献名称**：**"Recombinant endothelin-1 induces cell proliferation and extracellular matrix production in pulmonary artery smooth muscle cells"**
**作者**：Hynynen MM, et al.
**摘要**：通过体外重组EDN1蛋白处理肺动脉平滑肌细胞，发现其显著促进细胞增殖和胶原合成，提示EDN1可能在肺动脉高压等疾病中通过激活MAPK和PI3K通路发挥作用。
---
3. **文献名称**：**"Endothelin-1-mediated signaling in fibroblasts: role of recombinant protein in fibrosis models"**
**作者**：Khalil RA, et al.
**摘要**：研究利用重组EDN1蛋白刺激成纤维细胞，发现其通过激活TGF-β/Smad通路促进纤维化标志物(如α-SMA和胶原)表达，为抗纤维化药物开发提供了靶点。
---
4. **文献名称**：**"Functional characterization of recombinant human endothelin-1 in cardiovascular disease models"**
**作者**：Barton M, et al.
**摘要**：通过动物实验验证重组EDN1蛋白的生物学活性，证明其可诱导血管收缩和心肌肥厚，并揭示内皮素受体拮抗剂在治疗心血管疾病中的潜在价值。
---
以上文献涵盖了EDN1重组蛋白的制备、受体机制及疾病相关功能研究。如需具体领域(如肿瘤、代谢疾病)的文献，可进一步补充说明。
**Background of EDN1 Recombinant Protein**
Endothelin-1 (EDN1) is a 21-amino-acid vasoconstrictive peptide primarily produced by vascular endothelial cells. It belongs to the endothelin family, which includes EDN1. EDN2. and EDN3. and acts through G protein-coupled receptors (ETA and ETB). EDN1 is synthesized as a prepropeptide (prepro-EDN1) that undergoes proteolytic processing to release the mature, biologically active peptide. It plays critical roles in regulating vascular tone, cell proliferation, fibrosis, and inflammation. Dysregulation of EDN1 is implicated in cardiovascular diseases (e.g., hypertension, atherosclerosis), cancer progression, pulmonary fibrosis, and chronic kidney disease.
Recombinant EDN1 protein is produced using genetic engineering techniques, often in *E. coli* or mammalian expression systems, to ensure proper folding and post-translational modifications (e.g., disulfide bond formation). Its small size and cysteine-rich structure (containing two disulfide bonds) necessitate precise production methods to maintain bioactivity. Purification typically involves affinity chromatography and HPLC to achieve high purity.
In research, recombinant EDN1 is widely used to study endothelial dysfunction, drug discovery (e.g., endothelin receptor antagonists), and disease mechanisms. It also serves as a tool to investigate signaling pathways, such as MAPK/ERK and Rho kinase, which mediate its effects. Despite its therapeutic potential, EDN1's short half-life and pleiotropic effects limit direct clinical use, though it remains a valuable target for drug development.
Overall, recombinant EDN1 is a pivotal reagent for exploring vascular biology and pathophysiology, bridging basic research and translational applications.
×
